Stocktoria
Outlook Therapeutics, Inc. OTLK
Outlook Therapeutics, Inc. (OTLK) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.4M at a -4416.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
| ALGS | Aligos Therapeutics, Inc. | 2/9 | — | — | — |
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
FAQ
Is OTLK financially healthy?
Outlook Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does OTLK pay a dividend?
No, Outlook Therapeutics, Inc. does not currently pay a dividend.
How profitable is OTLK?
In FY2025, Outlook Therapeutics, Inc. had a net margin of -4416.2%.
What is the analyst price target for OTLK?
The average Wall-Street price target for Outlook Therapeutics, Inc. is $5.50, about 400.0% above the recent price, from 3 analysts (consensus: buy).
Is OTLK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Outlook Therapeutics, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.